51043-72-2

Basic information

• Product Name: DICYCLOPROPYLMETHYLAMINE HYDROCHLORIDE
• Synonyms: Dicyclopropylmethanamine hydrochloride;DICYCLOPROPYLMETHYLAMINE HYDROCHLORIDE;C,C-DICYCLOPROPYL-METHYLAMINE, HCL;Dicyclopropanemethanamine hydrochloride (1:1)
• CAS NO: 51043-72-2
• Molecular Formula: C7H14ClN
• Molecular Weight: 147.65
• Mol File: 51043-72-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: DICYCLOPROPYLMETHYLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DICYCLOPROPYLMETHYLAMINE HYDROCHLORIDE(51043-72-2)
• EPA Substance Registry System: DICYCLOPROPYLMETHYLAMINE HYDROCHLORIDE(51043-72-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 51043-72-2(Hazardous Substances Data)

Usage

General Description

Dicyclopropylmethylamine hydrochloride is a chemical compound with the molecular formula C8H17N?HCl. It is an organic compound and a hydrochloride salt of dicyclopropylmethylamine, which is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. The hydrochloride salt form of this compound makes it more stable and easier to handle in a laboratory setting. It is a clear to pale yellow liquid with a distinctive odor, and it is commonly used as a reagent in chemical reactions and as a building block for the synthesis of various organic compounds.

Upstream product

• 1121-37-5 dicyclopropyl ketone 
• 14300-33-5 dicyclopropylmethanol 
• 14937-45-2 cetyltributylphosphonium bromide 
• 1160756-79-5 C₁₁H₂₁NOS 

Relevant articles and documents

Discovery of 1-amino-5 H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders

The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1- {[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b] indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.

Imidazopyridines for the treatment of neurological disorders

Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.